CVRx (CVRX) Projected to Announce Quarterly Earnings on Thursday

Posted by Francis Steltz on Aug 4th, 2026

CVRx (NASDAQ:CVRX – Get Free Report) is anticipated to post its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to post earnings of ($0.52) per share and revenue of $15.5490 million for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

CVRx (NASDAQ:CVRX – Get Free Report) last announced its earnings results on Monday, May 11th. The company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.51) by $0.01. CVRx had a negative return on equity of 120.76% and a negative net margin of 89.14%.The company had revenue of $14.77 million for the quarter, compared to analyst estimates of $14.49 million. On average, analysts expect CVRx to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

CVRx Trading Up 6.2%

CVRx stock opened at $5.50 on Tuesday. The company has a debt-to-equity ratio of 2.01, a quick ratio of 8.89 and a current ratio of 10.20. The stock has a market cap of $145.97 million, a PE ratio of -2.72 and a beta of 0.81. The stock has a 50-day moving average of $5.27 and a two-hundred day moving average of $6.52. CVRx has a one year low of $4.37 and a one year high of $11.30.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on CVRX. Wall Street Zen upgraded shares of CVRx from a “sell” rating to a “hold” rating in a report on Saturday, June 27th. Canaccord Genuity Group reiterated a “buy” rating and issued a $10.00 target price on shares of CVRx in a research note on Tuesday, April 14th. Finally, Weiss Ratings downgraded shares of CVRx from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 6th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.50.

Check Out Our Latest Analysis on CVRX

Institutional Trading of CVRx

Hedge funds have recently added to or reduced their stakes in the company. Alliancebernstein L.P. grew its stake in shares of CVRx by 10.7% during the third quarter. Alliancebernstein L.P. now owns 17,560 shares of the company’s stock worth $142,000 after purchasing an additional 1,700 shares in the last quarter. Cresset Asset Management LLC raised its stake in CVRx by 3.5% in the second quarter. Cresset Asset Management LLC now owns 53,542 shares of the company’s stock valued at $315,000 after buying an additional 1,823 shares in the last quarter. Barclays PLC raised its stake in CVRx by 9.8% in the fourth quarter. Barclays PLC now owns 25,262 shares of the company’s stock valued at $179,000 after buying an additional 2,257 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in CVRx by 7.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 57,447 shares of the company’s stock worth $464,000 after buying an additional 3,804 shares during the last quarter. Finally, Bridgeway Capital Management LLC lifted its holdings in CVRx by 8.9% during the 3rd quarter. Bridgeway Capital Management LLC now owns 54,000 shares of the company’s stock worth $436,000 after buying an additional 4,400 shares during the last quarter. 75.27% of the stock is owned by hedge funds and other institutional investors.

About CVRx

(Get Free Report)

CVRx, Inc is a clinical-stage medical device company focused on developing a neuromodulation platform therapy for patients with cardiovascular disease. The company’s flagship product, the Barostim™ system, delivers targeted electrical stimulation to the carotid baroreceptors with the goal of modulating the body’s natural blood pressure control mechanisms. This minimally invasive, implantable therapy is designed to address unmet needs in individuals suffering from hypertension and heart failure.

The Barostim system is currently being evaluated in multiple clinical trials, including studies in resistant hypertension and advanced heart failure.